anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
Patients will be treated every two weeks with 200 mg of the anti-IL human monoclonal antibody-6Rα Sarilumab (Kevzara) with or without conventional DMARDs. Sarilumab administration will be subcutaneous (abdomen, thigh, or upper arm). The dose will be reduced to 150 mg in the event of neutropenia, thrombocytopenia, and elevated liver enzymes.
<P>PROBLEM TO BE SOLVED: To obtain a constipation ameliorant which is used without impairing various useful components contained in the culture solution of a bacterium belonging to the genus Aureobasidium, has excellent amelioration effect on constipation and is expected to have immunostimulation effect and food and beverage containing the same.  <P>SOLUTION: The active ingredients of the constipation ameliorant comprises a β-1,3-1,6-glucan-containing culture obtained by culturing a bacterium belonging to the genus Aureobasidium and a cell body of lactic acid bacterium. The bacterium belonging to the genus Aureobasidium is preferably Aureobasidium pullulans M-1(FERM P-19213). The constipation ameliorant comprises 1-40 mass% calculated as β-1,3-1,6-glucan of the culture and 4-95 mass% of the cell body of the lactic acid bacterium in the solid content. The lactic acid bacterium is preferably Enterococcus faecalis. The lactic acid bacterium is preferably a heat sterilized lactic acid bacterium.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Participants in the CPAP/NPPV group received for first CPAP using a neonatal ventilator. The recommended starting pressure for CPAP was +6 centimeter of water (cmH2O). Positive continuous pressure could be increased to a maximum of +8 cmH2O. Optimal positive end expiratory pressure (PEEP) was what could maintain SpO2 at 94 per cent using the lowest fraction of inspired oxygen. PEEP will be decreased progressively of 1cmH2O every 6 hours from the optimal PEEP when FiO2 was inferior to 30% and there is no increase of work of breath.
<P>PROBLEM TO BE SOLVED: To provide a method of preparing a plant extract containing large amounts of various effective components, and a cosmetic composition containing the extract as an active ingredient prepared by the method.  <P>SOLUTION: The method of preparing a plant extract includes a high-pressure enzymatic decomposition step of treating a raw material with an enzyme at a high pressure of 400-800 MPa, and the cosmetic composition contains, as an active ingredient, the plant extract prepared using the method. Preferably, the raw material is at least one selected from the group consisting of green tea, bamboo and adlay. Preferably, the enzyme is at least one selected from the group consisting of amylase, protease, glycosidase, lactase, sucrose and maltase. The plant extract prepared using the high-pressure enzymatic decomposition technique contains various kinds and large amounts of effective components compared to extracts prepared using other extraction techniques, such that the effects of the effective components can be maximized.  <P>COPYRIGHT: (C)2011,JPO&INPIT
As with other 5-HT1B/1D agonists, sensations of tightness, pain, pressure, and heaviness have been reported after treatment with MAXALT in the precordium, throat, neck and jaw. These events have not been associated with arrhythmias or definite ischemic ECG changes in clinical trials (one patient experienced chest pain with possible ischemic ECG changes). Because drugs in this class may cause coronary artery vasospasm, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal’s variant angina before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud’s syndrome following the use of any 5-HT1 agonist are candidates for further evaluation (see WARNINGS).

Rizatriptan should also be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs (see CLINICAL PHARMACOLOGY, Special Populations).

Renally Impaired Patients: Rizatriptan should be used with caution in dialysis patients due to a decrease in the clearance of rizatriptan (see CLINICAL PHARMACOLOGY, Special Populations).

Hepatically Impaired Patients: Rizatriptan should be used with caution in patients with moderate hepatic insufficiency due to an increase in plasma concentrations of approximately 30% (see CLINICAL PHARMACOLOGY, Special Populations).

For a given attack, if a patient has no response to the first dose of rizatriptan, the diagnosis of migraine should be reconsidered before administration of a second dose.
The invention discloses a traditional Chinese medicine composition for treating chronic prostatitis. Majority of chronic prostatitis is related to accumulation of damp heat and evil poison in lower energizer and blockage of meridians due to blood stasis, namely, the main pathogenesis is characterized in that damp, heat, turbidity toxin and stasis are accumulated in essence chamber. The traditional Chinese medicine composition for treating chronic prostatitis is prepared by traditional Chinese medicines with functions of clearing heat and removing toxicity, promoting diuresis and discharging turbidity, and promoting blood circulation to remove stasis. The traditional Chinese medicines comprise pteris cretica, wilson barberry, cyclea barbata miers, cordate houttuynia, heterohairy monkshood root, tree falsespiraea bark, securidaca inappendiculata hassk, puberulous glochidion branchlet and leaf, hollow wood, latouchea gokiensis and willow herb. The traditional Chinese medicines are decocted with water into decoction. By clinical experiments, a total effective rate reaches 90.0% which is much better than the total effective rate being 64.0% of a control group; and the traditional Chinese medicine composition for treating chronic prostatitis is significant in curative effect and few in side effects.
PROBLEM TO BE SOLVED: To obtain a skin-protecting agent having affinity to the skin, useful for keeping the moistness of the skin and shielding harmful ultraviolet rays by using an alcoholic extract of garden balsam. SOLUTION: A skin-protecting agent is produced by using an alcoholic extract of garden balsam as it is or as a cosmetic or a bathing agent. In the case of the single use of the extract, it is mixed with a water-soluble polymer to form a jelly cream. In the case of applying to a cosmetic, 0.5-2 pts.wt. of the extracted liquid is mixed to 10 pts.wt. of the cosmetic and, in the case of applying to a bathing agent, 1-2 pts.wt. of the extract is mixed to 10 pts.wt. of a bathing agent or 3-7 mL of the extracted liquid is poured into a bathtub.  The extract can be produced by harvesting the whole grass (including seed) of garden balsam in the flowering stage, optionally drying in the sun and cutting the dried product, immersing 2-5 pts.wt. of the obtained material in 10 pts.wt. of an aqueous solution containing ethyl alcohol having a concentration of >=10% (e.g. white liquor) for 2 weeks to half a year and separating the extraction residue.
Ustekinumab for 52 weeks. The dose will be determined by the participant's body weight.
The One Flare file will be used with a rotational speed of 300 rpm and 3 N/cm torque at a working length of 3 mm. After the Wave One Gold file will be used with the VDW endodontic motor (VDW) in accordance with the manufacturer's recommendations.
BACKGROUND: Recent studies demonstrated that restoring sagittal alignment to the original Roussouly type can remarkably reduce complication rates after adult spinal deformity surgery. However, there is still no data proving the benefit of maintaining ideal Roussouly shape in the lumbar degenerative diseases and its association with the development of adjacent segment disease (ASD). Thus, this study was performed to validate the usefulness of Roussouly classification to predict the occurrence of ASD after lumbar fusion surgery.
MATERIALS AND METHODS: This study retrospectively reviewed 234 consecutive patients with lumbar degenerative diseases who underwent 1- or 2-level fusion surgery. Demographic and radiographic data were compared between ASD and non-ASD groups. The patients were classified by both "theoretical" [based on pelvic incidence (PI)] and "current" (based on sacral slope) Roussouly types. The patients were defined as "matched" if their "current" shapes matched the "theoretical" types and otherwise as "mismatched". The logistic regression analysis was performed to identify the factors associated with ASD. Finally, clinical data and spinopelvic parameters of "theoretical" and "current" types were compared.
RESULTS: With a mean follow-up duration of 70.6 months, evidence of ASD was found in the 68 cases. Postoperatively, ASD group had more "current" shapes classified as type 1 or 2 and fewer as type 3 than the non-ASD group (p < 0.001), but the distribution of "theoretical" types was similar between groups. Moreover, 80.9% (55/68) of patients with ASD were mismatched, while 48.2% (80/166) of patients without ASD were mismatched (p < 0.001). A multivariate analysis identified age [odds ratio (OR) = 1.058)], 2-level fusion (OR = 2.9830), postoperative distal lordosis (DL, OR = 0.949) and mismatched Roussouly type (OR = 4.629) as independent risk factors of ASD. Among the four "theoretical" types, type 2 had the lowest lumbar lordosis, DL, and segmental lordosis. When considering the "current" types, current type 2 was associated with higher rates of 2-level fusion, worse DL, and greater pelvic tilt compared with other current types.
CONCLUSIONS: DL loss and mismatched Roussouly type were significant risk factors of ASD. To decrease the incidence of ASD, an appropriate value of DL should be achieved to restore sagittal alignment back to the ideal Roussouly type.
LEVEL OF EVIDENCE: Level 4.
The present invention relates to a polymer nanometer particle, a medicine capsule and the preparation thereof. The polymer nanometer particle is composed of the following components: 85 to 95 wt% of degradation type high molecules composed of polylactic acid and a derivative thereof, and 5 to 15 wt% of surface stabilizing agent macromolecules composed of a non-ionic macromolecule surfactant and other polyelectrolyte mixtures. A degradation type macromolecule solution is added into the water containing a surface stabilizing agent to form a water-in-oil structure. After the agitation of one hour, a milky solution is obtained. Finally, the nanometer particle can be obtained by an ultrasonic emulsifying method. The medicine capsule is formed by that water-soluble small molecule medicines are sealed in the nanometer particles composed of the degradation type high molecules and the surface stabilizing agent macromolecules, and the solid content of the small molecule medicines in the nanometer particles is from 1 to 10%. As a result, the present invention has the characteristics that the present invention has simple preparation technology and reduces preparation cost; besides, the present invention can perfectly control the mechanism of degradation and release, greatly widen the application area, etc.
During the last few years, cell-free DNA (cfDNA) has emerged as a possible non-invasive biomarker for prediction of complications after lung transplantation. We previously published a proof-of-concept study using a digital droplet polymerase chain reaction (ddPCR)-based method for detection of cfDNA. In the current study, we aimed to further evaluate the potential clinical usefulness of detecting chronic lung allograft dysfunction (CLAD) using three different ddPCR applications measuring and calculating the donor fraction (DF) of cfDNA as well as one method using the absolute amount of donor-derived cfDNA. We analyzed 246 serum samples collected from 26 lung transplant recipients. Nine of the patients had ongoing CLAD at some point during follow-up. All four methods showed statistically significant elevation of the measured variable in the CLAD samples compared to the non-CLAD samples. The results support the use of ddPCR-detected cfDNA as a potential biomarker for prediction of CLAD. These findings need to be validated in a subsequent prospective study.
OBJECTIVE: This systematic review aimed to assess the different treatments of benign maxillo-mandibular radiolucent bone lesions over 4 cm to propose a management algorithm.
STUDY DESIGN: A literature search was conducted using MEDLINE/PubMed, Scopus, Google Scholar, Virtual Health Library databases, and gray literature. Randomized or non-randomized clinical trials and case series with 10 or more patients with a minimum follow up of 1 year, published in French or English until August 2023, were included. The risk of bias was assessed for all papers included.
RESULTS: Of 1433 records identified, 22 were included in this review, reporting data from 1364 lesions. Ameloblastoma was the most common lesion (51.22%) and mandible was the most common site (81.21%). Initial conservative treatment was prevalent (71.04%). Recurrence was higher after conservative (13.8%) than after radical treatments (6.5%). Multilocularity, cortical perforation, dental element preservation were linked to a higher recurrence risk.
CONCLUSION: This study has shown importance of understanding specific characteristics and recurrence risk in benign maxillomandibular osteolytic lesions. Multidisciplinary team approval, personalized approach based on lesion type and patient are crucial. The presence of at least one risk factor could lead to therapeutic decision. Despite limitations, the study informed lesion management and provided precise recommendations.
Inflammation is a biodefense mechanism that provides protection against painful conditions such as inflammatory bowel disease, other gastrointestinal problems, and irritable bowel syndrome. Paraprobiotics have probiotic characteristics of intestinal modulation along with merits of safety and stability. In this study, heat-killed Lactiplantibacillus plantarum KU15122 (KU15122) was investigated for its anti-inflammatory properties. KU15122 was subjected to heat-killed treatment for enhancement of its safety, and its concentration was set at 8 log CFU/mL for conducting different experiments. Nitric oxide production was most remarkably reduced in the KU15122 group, whereas it was increased in the LPS-treated group. In RAW 264.7 cells, KU15122 inhibited the expression of inducible nitric oxide synthase, cyclooxygenase-2, interleukin (IL)-1β, IL-6, and tumor necrosis factor-α. ELISA revealed that among the tested strains, KU15122 exhibited the most significant reduction in PGE2, IL-1β, and IL-6. Moreover, KU15122 inhibited various factors involved in the nuclear factor-kappa B, activator protein-1, and mitogen-activated protein kinase pathways. In addition, KU15122 reduced the generation of reactive oxygen species. The anti-inflammatory effect of KU15122 was likely attributable to the bacterial exopolysaccharides. Conclusively, KU15122 exhibits anti-inflammatory potential against inflammatory diseases.
BACKGROUND: To provide patients the chance of accepting curative transjugular intrahepatic portosystemic shunt (TIPS) rather than palliative treatments for portal hypertension-related variceal bleeding and ascites, we aimed to assess hepatic-associated vascular morphological change to improve the predictive accuracy of overt hepatic encephalopathy (HE) risks.
METHODS: In this multicenter study, 621 patients undergoing TIPS were subdivided into training (413 cases from 3 hospitals) and external validation datasets (208 cases from another 3 hospitals). In addition to traditional clinical factors, we assessed hepatic-associated vascular morphological changes using maximum diameter (including absolute and ratio values). Three predictive models (clinical, hepatic-associated vascular, and combined) were constructed using logistic regression. Their discrimination and calibration were compared to test the necessity of hepatic-associated vascular assessment and identify the optimal model. Furthermore, to verify the improved performance of ModelC-V, we compared it with four previous models, both in discrimination and calibration.
RESULTS: The combined model outperformed the clinical and hepatic-associated vascular models (training: 0.814, 0.754, 0.727; validation: 0.781, 0.679, 0.776; p < 0.050) and had the best calibration. Compared to previous models, ModelC-V showed superior performance in discrimination. The high-, middle-, and low-risk populations displayed significantly different overt HE incidence (p < 0.001). Despite the limited ability of pre-TIPS ammonia to predict overt HE risks, the combined model displayed a satisfactory ability to predict overt HE risks, both in the low- and high-ammonia subgroups.
CONCLUSION: Hepatic-associated vascular assessment improved the predictive accuracy of overt HE, ensuring curative chances by TIPS for suitable patients and providing insights for cirrhosis-related studies.
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin having excellent releasing properties and stability of urea in the external preparation for the skin comprising water, the urea, a gelling agent and a polyhydric alcohol.  <P>SOLUTION: The external preparation for the skin comprises the urea in an amount of 5-20 pts. wt. based on 1 pt. wt. of the gelling agent and the water in an amount of 5-35 pts. wt. based on 1 pt. wt. of the gelling agent and further contains 0.1-20 wt.% of the polyhydric alcohol. The safe external preparation for the skin has excellent releasing properties and stability of the urea without irritation.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
With the rapid advancements in molecular biology and genomics, a multitude of connections between RNA and diseases has been unveiled, making the efficient and accurate extraction of RNA-disease (RD) relationships from extensive biomedical literature crucial for advancing research in this field. This study introduces RDscan, a novel text mining method developed based on the pre-training and fine-tuning strategy, aimed at automatically extracting RD-related information from a vast corpus of literature using pre-trained biomedical large language models (LLM). Initially, we constructed a dedicated RD corpus by manually curating from literature, comprising 2,082 positive and 2,000 negative sentences, alongside an independent test dataset (comprising 500 positive and 500 negative sentences) for training and evaluating RDscan. Subsequently, by fine-tuning the Bioformer and BioBERT pre-trained models, RDscan demonstrated exceptional performance in text classification and named entity recognition (NER) tasks. In 5-fold cross-validation, RDscan significantly outperformed traditional machine learning methods (Support Vector Machine, Logistic Regression and Random Forest). In addition, we have developed an accessible webserver that assists users in extracting RD relationships from text. In summary, RDscan represents the first text mining tool specifically designed for RD relationship extraction, and is poised to emerge as an invaluable tool for researchers dedicated to exploring the intricate interactions between RNA and diseases. Webserver of RDscan is free available at https://cellknowledge.com.cn/RDscan/.
The invention belongs to the technical field of medicines, and relates to an EV71VP1 protein-containing nanoparticle and a preparation method thereof. In particular, the invention relates to a nanoparticle comprising the EV71VP1 protein, an immunoadjuvant selected from one or more of TNF-a, CpG, bcg and flagellin, a cationic polymer and an anionic polymer. The invention also relates to a method for preparing said nanoparticles, an immunogenic composition (e.g. a vaccine) comprising said nanoparticles, the use of said nanoparticles for preparing an immunogenic composition (e.g. a vaccine), and the use of said nanoparticles or immunogenic composition (e.g. a vaccine) for eliciting or enhancing an immune response to EV71 in a subject.
Pharmaceutical compsns. consist of an antimicrobial (I) covalently attached to a carrier molecule (II) which is so big that it is unable to migrate through the skin, mucous membranes or skin wounds. Pref. the molecules of (I) are sufficiently small that they can migrate through the skin etc. and are esp. those which will cause toxic side effects if introduced into the main blood stream. (II) are esp. natural or modified polysaccharides, natural or synthetic polypeptides, glass (opt. with attached functional gps.) or synthetic polymers. (I) are immobilised without loss of antimicrobial activity. The compsns. may be used, for animals or humans, topically or by introduction into the gastro-intestinal tract without the dangers of resorption of highly toxic antibiotics, of dilution by migration or of inducing sensitisation. In an example, bacitracin A is attached via an amino gp. to cellulose.
Here the investigator plan to investigate the effect of tFUS on motor behavior. M1 has been chosen for two fundamental reasons for this study: 1) The use of muscle contraction to generate a detectable evoked potential signal allows for targeting of a precise area within M1 with tFUS, and 2) It is known that M1 is involved in fast learning of sequential motor tasks By targeting M1 with tFUS in neurologically healthy volunteers, we can study the effects of tFUS on motor learning measures (e.g., reaction time, accuracy) while a subject is performing a finger tapping motor learning task. If ultrasound is proven efficacious for stimulating the motor cortex, non-surgical ultrasound could potentially replace costly and risky surgery for the treatment of brain disorders as is common with deep brain stimulation for essential tremor or Parkinson's disease. There is currently no way to affect brain tissue deep into the cortex without surgery, genetic alteration or viral vectors (the latter two are not approved for human use). This technology is non-surgical and as invasive as any diagnostic ultrasound exam. With success, transcranial focused ultrasound could become useful world-wide as a cheap, portable and effective tool for human brain mapping efforts as well as for the diagnosis and potential treatment of a broad range of psychiatric and neurological disorders.
Single oral dose of ozanimod 0.92 mg using Sprinkle capsule. Ozanimod Sprinkle Capsule will be opened, and the entire contents sprinkled onto a teaspoon (5 mL) of applesauce.
FIELD: medicine; dentistry.SUBSTANCE: group of inventions relates to oral care. Composition for oral care contains serine in amount of 0.05 wt. % to 0.39 wt. % of total weight of composition, zinc oxide in amount of 1 wt. %, zinc citrate in amount of 0.5 wt. % of total weight of composition and abrasive, where abrasive is chosen from silicon oxide or natural calcium carbonate. Also disclosed is a method for reducing or inhibiting the formation of biofilm in the oral cavity, involving contacting the oral cavity with the oral care composition.EFFECT: group of inventions provides reduced biofilm formation in the oral cavity.11 cl, 3 ex, 3 tbl